Uterine Cancer Clinical Trial
Official title:
Rapid First Contact Using Virtual Visits to Improve Time-To-Treatment for Patients With Uterine Cancer
This project aims to evaluate whether rapid first contact with the oncologist the same day or the next day after pathologic diagnosis contributes to a decreased time to treatment, decreased patient anxiety and increased patient satisfaction.
Time to treatment (time from disease diagnosis to initiation of treatment) impacts outcomes
in uterine cancer. When controlled for stage, patients with longer time to treatment tend to
have less favorable outcomes. Similarly, longer time to treatment has a negative impact on
patients' quality of life and markers for anxiety. Our experience at this institution
suggests that the time to referral (time from uterine cancer diagnosis and the patients'
first encounter with the oncologist) is variable and presents the greatest opportunity for
decreasing time to treatment. Among the factors that contribute to the time to referral are
the time taken by the referring provider to relay the diagnosis to the patient, time taken to
schedule an appointment with the specialist, and the patient's availability to keep an
appointment.
Virtual visits provide an opportunity to expedite consultation with the treating oncologist
by removing some of the barriers that delay face-to-face visits. Among these barriers are
patients' availability for a short notice face-to-face visit based on their work or family
obligations, access to transportation, and mental preparedness.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03285802 -
Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
|
Phase 2/Phase 3 | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Not yet recruiting |
NCT06369155 -
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
|
Phase 2 | |
Not yet recruiting |
NCT05998811 -
Insights Into Participating in Studies for Uterine Cancer
|
||
Completed |
NCT01399658 -
Image-Guided Gynecologic Brachytherapy
|
Phase 2 | |
Completed |
NCT01432015 -
Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
|
Phase 4 | |
Recruiting |
NCT02349958 -
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy
|
Phase 2 | |
Completed |
NCT00581646 -
Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
|
N/A | |
Completed |
NCT00284427 -
Safety of Antioxidants During GYN Cancer Care
|
Phase 2 | |
Completed |
NCT00147680 -
Uterine Papillary Serous Cancer (UPSC) Trial
|
Phase 2 | |
Recruiting |
NCT05743517 -
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
|
N/A | |
Recruiting |
NCT05916196 -
[18F]FES PET/.CT in Uterine Cancer
|
Phase 2 | |
Withdrawn |
NCT04368130 -
SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care
|
N/A | |
Active, not recruiting |
NCT03668340 -
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
|
Phase 2 | |
Completed |
NCT00588640 -
Study of D-Methadone in Patients With Chronic Pain
|
Phase 1/Phase 2 | |
Recruiting |
NCT05990426 -
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
|
N/A | |
Completed |
NCT03701529 -
Effect of Anesthetic Agents on Optic Nerve Sheath Diameter
|
N/A | |
Recruiting |
NCT05758688 -
Whole Pelvis Proton Radiation for Gynecologic Cancer
|
N/A | |
Completed |
NCT01953107 -
Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.
|
Phase 4 |